EP3436590A4 - Trans-splicing rna (tsrna) - Google Patents

Trans-splicing rna (tsrna) Download PDF

Info

Publication number
EP3436590A4
EP3436590A4 EP17776008.9A EP17776008A EP3436590A4 EP 3436590 A4 EP3436590 A4 EP 3436590A4 EP 17776008 A EP17776008 A EP 17776008A EP 3436590 A4 EP3436590 A4 EP 3436590A4
Authority
EP
European Patent Office
Prior art keywords
tsrna
trans
splicing rna
splicing
rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP17776008.9A
Other languages
German (de)
French (fr)
Other versions
EP3436590A1 (en
Inventor
Volker Patzel
Sushmita PODDAR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National University of Singapore
Original Assignee
National University of Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National University of Singapore filed Critical National University of Singapore
Publication of EP3436590A1 publication Critical patent/EP3436590A1/en
Publication of EP3436590A4 publication Critical patent/EP3436590A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
EP17776008.9A 2016-04-01 2017-03-31 Trans-splicing rna (tsrna) Pending EP3436590A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201605586 2016-04-01
PCT/SG2017/050183 WO2017171654A1 (en) 2016-04-01 2017-03-31 Trans-splicing rna (tsrna)

Publications (2)

Publication Number Publication Date
EP3436590A1 EP3436590A1 (en) 2019-02-06
EP3436590A4 true EP3436590A4 (en) 2019-12-04

Family

ID=59966148

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17776008.9A Pending EP3436590A4 (en) 2016-04-01 2017-03-31 Trans-splicing rna (tsrna)

Country Status (7)

Country Link
US (2) US11517583B2 (en)
EP (1) EP3436590A4 (en)
JP (2) JP7229467B2 (en)
CN (1) CN109642241B (en)
AU (1) AU2017240703B2 (en)
SG (1) SG11201808538QA (en)
WO (1) WO2017171654A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021076656A1 (en) * 2019-10-15 2021-04-22 University Of Massachusetts Rna editor-enhanced rna trans-splicing
EP4100533A1 (en) * 2020-02-07 2022-12-14 University of Rochester Ribozyme-mediated rna assembly and expression
GB202102118D0 (en) 2021-02-15 2021-03-31 Cambridge Entpr Ltd RNA Trans-Splicing molecule
GB202108855D0 (en) 2021-06-21 2021-08-04 Cambridge Entpr Ltd Methods of eukaryotic gene expression
AU2022337146A1 (en) * 2021-09-03 2024-03-14 Tacit Therapeutics, Inc. Rna editing via recruitment of spliceosome components
WO2023140792A2 (en) * 2022-01-18 2023-07-27 National University Of Singapore TRANS-SPLICING RNA (tsRNA)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997022250A1 (en) * 1995-12-15 1997-06-26 Intronn Llc Therapeutic molecules generated by trans-splicing
WO2002097080A2 (en) * 2002-04-30 2002-12-05 Icon Genetics Ag Amplification vectors based on trans-splicing
WO2003016537A2 (en) * 2001-08-13 2003-02-27 Aescu-Life Gmbh Method for repairing a mutant rna from a dna with genetic defects and for the programmed death of tumour cells by rna trans-splicing as well as a method for identifying naturally trans-spliced cellular rna
WO2003104412A2 (en) * 2002-06-05 2003-12-18 Intronn, Inc. Spliceosome mediated rna trans-splicing and correction of factor viii genetic defects using spliceosome mediated rna trans spling
WO2013025461A1 (en) * 2011-08-12 2013-02-21 Virxsys Corporation Compositions and methods for inducing apoptosis
EP2924115A1 (en) * 2012-11-21 2015-09-30 National Cancer Center Recombinant adenovirus with increased safety and anticancer activities, and use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6280978B1 (en) * 1995-12-15 2001-08-28 Intronn Holdings, Llc Methods and compositions for use in spliceosome mediated RNA trans-splicing
JP4654033B2 (en) * 2002-10-23 2011-03-16 バークシス コーポレーション Screening method for efficient pre-trans-splicing molecule identification
US7192709B2 (en) 2004-03-15 2007-03-20 Digigenomics Co., Ltd. Methods for identification, assessment, prevention, and therapy of cancer
KR100958293B1 (en) * 2008-03-27 2010-05-19 단국대학교 산학협력단 Allosteric trans?splicing group I ribozyme whose activity of target-specific RNA replacement is controlled by theophylline
KR20110036996A (en) 2009-10-05 2011-04-13 전남대학교산학협력단 Ho-1, a marker for diagnosing squamous cell carcinoma and uses thereof
WO2012056441A1 (en) * 2010-10-28 2012-05-03 Nanodoc Ltd. Compositions and methods for specific cleavage of exogenous rna in a cell
KR101293620B1 (en) * 2011-08-19 2013-08-13 국립암센터 Recombinant adenovirus comprising trans-splicing ribozyme and therapeutic genes having anti-cancer activity and the Use thereof
GB201219762D0 (en) * 2012-11-02 2012-12-19 Bauer Johann A RNA trans-splicing molecule (RTM) for use in the treatment of cancer
US20140283156A1 (en) * 2013-03-14 2014-09-18 Cold Spring Harbor Laboratory Trans-splicing ribozymes and silent recombinases

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997022250A1 (en) * 1995-12-15 1997-06-26 Intronn Llc Therapeutic molecules generated by trans-splicing
WO2003016537A2 (en) * 2001-08-13 2003-02-27 Aescu-Life Gmbh Method for repairing a mutant rna from a dna with genetic defects and for the programmed death of tumour cells by rna trans-splicing as well as a method for identifying naturally trans-spliced cellular rna
WO2002097080A2 (en) * 2002-04-30 2002-12-05 Icon Genetics Ag Amplification vectors based on trans-splicing
WO2003104412A2 (en) * 2002-06-05 2003-12-18 Intronn, Inc. Spliceosome mediated rna trans-splicing and correction of factor viii genetic defects using spliceosome mediated rna trans spling
WO2013025461A1 (en) * 2011-08-12 2013-02-21 Virxsys Corporation Compositions and methods for inducing apoptosis
EP2924115A1 (en) * 2012-11-21 2015-09-30 National Cancer Center Recombinant adenovirus with increased safety and anticancer activities, and use thereof

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
C. GRUBER ET AL: "Spliceosome-Mediated RNA Trans-Splicing Facilitates Targeted Delivery of Suicide Genes to Cancer Cells", MOLECULAR CANCER THERAPEUTICS, vol. 10, no. 2, 1 February 2011 (2011-02-01), pages 233 - 241, XP055099155, ISSN: 1535-7163, DOI: 10.1158/1535-7163.MCT-10-0669 *
CHRISTINA GRUBER ET AL: "The design and optimization of RNA trans-splicing molecules for skin cancer therapy", MOLECULAR ONCOLOGY, vol. 7, no. 6, 1 December 2013 (2013-12-01), pages 1056 - 1068, XP055099110, ISSN: 1574-7891, DOI: 10.1016/j.molonc.2013.08.005 *
DALLINGER ET AL: "Development of spliceosome-mediated RNA trans-splicing (SMaRT) for the correction of inherited skin diseases.", EXPERIMENTAL DERMATOLOGY, vol. 12, no. 1, 1 February 2003 (2003-02-01), pages 37 - 46, XP055087685, ISSN: 0906-6705, DOI: 10.1034/j.1600-0625.2003.120105.x *
PODDAR SUSHMITA ET AL: "RNA Structure Design Improves Activity and Specificity of trans-Splicing-Triggered Cell Death in a Suicide Gene Therapy Approach.", MOLECULAR THERAPY. NUCLEIC ACIDS, vol. 11, 1 June 2018 (2018-06-01), pages 41 - 56, XP002795081, ISSN: 2162-2531, DOI: 10.1016/j.omtn.2018.01.006 *
PODDAR SUSHMITA ET AL: "Supplemental Information to RNA Structure Design Improves Activity and Specificity of trans-Splicing-Triggered Cell Death in a Suicide Gene Therapy Approach.", MOLECULAR THERAPY. NUCLEIC ACIDS, vol. 11, 1 June 2018 (2018-06-01), pages 1 - 31, XP002795275, ISSN: 2162-2531, DOI: 10.1016/j.omtn.2018.01.006 *
SUSHMITA PODDAR: "RNA trans-splicing for selective killing of virus-transduced or cancer cells", A THESIS SUBMITTED FOR THE DEGREE OF DOCTOR OF PHILOSOPHY DEPARTMENT OF MICROBIOLOY AND IMMUNOLOGY, 21 January 2016 (2016-01-21), pages 1 - 236, XP002795080, Retrieved from the Internet <URL:https://scholarbank.nus.edu.sg/bitstream/10635/143282/1/SUSHMITA%20PODDAR_A0092773W_THESIS_08_05_2016.pdf> [retrieved on 20191018] *
VERENA WALLY ET AL: "Spliceosome-Mediated Trans-Splicing: The Therapeutic Cut and Paste", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 132, no. 8, 12 April 2012 (2012-04-12), pages 1959 - 1966, XP055087606, ISSN: 0022-202X, DOI: 10.1038/jid.2012.101 *
YUN-HEE KIM ET AL: "Image-aided Suicide Gene Therapy Utilizing Multifunctional hTERT-targeting Adenovirus for Clinical Translation in Hepatocellular Carcinoma", THERANOSTICS, vol. 6, no. 3, 1 January 2016 (2016-01-01), AU, pages 357 - 368, XP055275474, ISSN: 1838-7640, DOI: 10.7150/thno.13621 *

Also Published As

Publication number Publication date
US20240075051A1 (en) 2024-03-07
CN109642241A (en) 2019-04-16
SG11201808538QA (en) 2018-10-30
US20190111072A1 (en) 2019-04-18
JP7229467B2 (en) 2023-02-28
AU2017240703B2 (en) 2020-05-21
WO2017171654A1 (en) 2017-10-05
JP2019509756A (en) 2019-04-11
AU2017240703A1 (en) 2018-10-18
CN109642241B (en) 2023-06-27
EP3436590A1 (en) 2019-02-06
US11517583B2 (en) 2022-12-06
JP2023055809A (en) 2023-04-18

Similar Documents

Publication Publication Date Title
EP3638215A4 (en) Rna formulations
EP3668971A4 (en) Rna polymerase variants
EP3430731A4 (en) Iugw architecture
EP3313989A4 (en) Modified crispr rna and modified single crispr rna and uses thereof
EP3262537A4 (en) Contextual discovery
EP3494682A4 (en) Security-on-demand architecture
EP3409780A4 (en) Nucleic acid complex
EP3360426A4 (en) Food-improving agent
EP3436590A4 (en) Trans-splicing rna (tsrna)
EP3268336A4 (en) Solid-rocket propellants
EP3498724A4 (en) Nucleic acid complex
EP3673066A4 (en) Rna molecules
EP3395436A4 (en) Microreactor
EP3427743A4 (en) Anti-hepatoma-virus agent
EP3405500A4 (en) Maltosyl-isomaltooligosaccharides
EP3363449A4 (en) Muscle-enhancing agent
EP3295959A4 (en) Cmlck gene introduction
EP3265558A4 (en) Stabilized rna solutions
EP3468071A4 (en) Data center
AU2016363347B2 (en) Marking-out aid
AU2017903773A0 (en) RNA molecules
AU2016903133A0 (en) Blocksock
AU2016902907A0 (en) Improved Camber-Inducer
AU2016903015A0 (en) BootOver
AU2016902910A0 (en) BoardCarry

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20181029

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/63 20060101ALI20191022BHEP

Ipc: C12N 15/67 20060101ALI20191022BHEP

Ipc: C12N 15/11 20060101AFI20191022BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20191105

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/63 20060101ALI20191028BHEP

Ipc: C12N 15/11 20060101AFI20191028BHEP

Ipc: C12N 15/67 20060101ALI20191028BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20210526

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS